[关键词]
[摘要]
目的 探讨赖氨酸磷酸氢钙颗粒联合重组人生长激素治疗特发性矮小症患儿的临床疗效。方法 选择2018年8月—2019年8月在漯河市第三人民医院治疗的96例特发性矮小症患儿,根据用药差别分成对照组和治疗组,每组各48例。对照组患者皮下注射重组人生长激素注射液,0.033~0.050 mg/kg,1次/d;治疗组在对照组基础上口服赖氨酸磷酸氢钙颗粒,5 g/次,2次/d。两组患者均经12个月治疗。观察两组患者临床疗效,比较治疗前后两组患者身高、体质量、生长速度、骨龄,血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)、25羟维生素D[25-(OH)D]、摄食抑制因子1(Nesfatin-1)、生长激素释放肽(Ghrelin)、骨钙素(OC)、Ⅰ型胶原交联羧基末端肽(ICTP)、骨特异性碱性磷酸酶(BAP)和Ⅰ型前胶原氨基端前肽(PINP)水平。结果 经治疗,治疗组总有效率明显高于对照组(97.92% vs 83.33%,P<0.05)。治疗后,两组患儿身高、体质量、生长速度、骨龄均明显高于治疗前(P<0.05),且治疗组明显高于对照组(P<0.05)。治疗后,两组血清IGF-1、IGFBP-3和25-(OH) D水平显著升高,而Nesfatin-1和Ghrelin水平显著降低(P<0.05),且治疗组患者血清学指标明显好于对照组(P<0.05)。经治疗,两组血清OC、ICTP、BAP、PINP水平均显著升高(P<0.05),且治疗组明显高于对照组(P<0.05)。结论 赖氨酸磷酸氢钙颗粒联合重组人生长激素治疗特发性矮小症患儿可有效促进患儿身高增长,促进骨代谢指标的改善,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules combined with recombinant human growth hormone in treatment of idiopathic dwarfism in children. Methods Children (98 cases) with idiopathic dwarfism in Luohe Third People's Hospital from August 2018 to August 2019 were divided into control and treatment groups according to the difference of drugs, and each group had 48 cases. Children in the control group were hypodermic injection administered with Recombinant Human Growth Hormone Injection, 0.033 — 0.050 mg/kg, once daily. Children in the treatment group po administered with Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules on the basis of the control group, 5 g/time, twice daily. Children in two groups were treated for 12 months. After treatment, the clinical efficacy was evaluated, and the height, weight, growth rate, and bone age, and serum levels of IGF-1, IGFBP-3, 25-(OH) D, Nesfatin-1, Ghrelin, OC, ICTP, BAP, and PINP in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.92% vs 83.33%, P<0.05). After treatment, the height, body mass, growth rate, and bone age in the two groups were significantly higher than those before treatment (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of IGF-1, IGFBP-3, and 25-(OH) D in two groups were significantly increased, while the levels of Nesfatin-1 and Ghrelin were significantly decreased (P<0.05), and these serological indexes in treatment group were significantly better than those in control group (P<0.05). After treatment, the serum levels of OC, ICTP, BAP, and PINP in two groups were significantly increased, and which in treatment group were significantly higher than those in control group (P<0.05). Conclusion Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules combined with recombinant human growth hormone in treatment of idiopathic dwarfism in children can effectively promote children's height and improve the indexes of bone metabolism, which has a certain clinical application value.
[中图分类号]
R985
[基金项目]
河南省医学科技攻关计划项目(20140516)